Commentary|Articles|November 16, 2026

Greece’s healthcare system shows the limits of universal coverage

Listen
0:00 / 0:00

A system can cover its population and still struggle with access, workforce capacity and the cost of care

Greece provides universal healthcare coverage. Its average life expectancy is 82.2 years, among the highest in Europe, and its healthcare system has recovered from the global financial crisis and the COVID-19 pandemic. Those are meaningful achievements. But coverage has not resolved the system’s structural problems. Patients still face significant out-of-pocket costs, healthcare resources remain concentrated in major cities, and an aging population is increasing demand for services. Greece illustrates a distinction that matters to every healthcare system: coverage is not the same as access.

In September 2026, the TPG International Health Academy brought 20 American healthcare executives and sponsors to Athens to examine how the Greek system is organized and financed. We met with health officials, academics, hospital leaders and pharmaceutical experts and visited public and private healthcare facilities. The discussions offered a direct look at the tradeoffs facing a country that provides universal coverage while managing financial and demographic pressure.

Greece spends approximately 10% of its gross domestic product on healthcare, compared with 18% in the United States. Roughly two-thirds of Greek healthcare spending comes from the public sector and its social security mechanism. The system supports 245 hospitals, with about two-thirds of beds in publicly owned facilities. Greece recently recorded a government budget surplus and is in its strongest fiscal position in a generation, but its high public debt continues to constrain public spending decisions. The healthcare system also faces continuing budget deficits.

Greek doctors are seeking opportunities outside the country

Access is one of the clearest challenges. Greece has two major urban centers, Athens and Thessaloniki, alongside mountainous regions and 227 inhabited islands. Healthcare professionals and facilities are concentrated in the cities. In some remote communities, serious emergencies may require ferry or helicopter transport. Universal coverage offers little help to a patient who cannot reach a provider in time.

The workforce problem makes that gap harder to close. More than 5,000 Greek doctors sought professional opportunities outside the country over the past five years. The continued loss of clinicians places added pressure on services, particularly in rural areas. Greece has responded in part through digital infrastructure. Its National Telemedicine Network connects 82 hospitals with 380 remote areas, giving practitioners access to specialist resources and clinical decision support. Electronic prescriptions and a national electronic health record also support information sharing across public and private providers.

But technology cannot replace clinical capacity. Rural communities still face provider shortages and digital literacy barriers. AI-assisted radiology and pathology applications are being piloted in university hospitals, but broader use depends on adequate hardware, reliable data and workforce training. The lesson is familiar to U.S. health systems: technology can extend the reach of existing resources, but it cannot substitute for the people and infrastructure required to deliver care.

Payment reform presents another set of tradeoffs. Greece replaced a retrospective hospital payment model, which contributed to high costs, long stays and accumulated arrears, with a version of diagnosis-related group payment. The change created incentives for efficiency but also raised concerns about upcoding. As in the United States, reimbursement must control spending without rewarding behavior that works against quality or appropriate care.

Pharmaceutical policy reflects the same tension between affordability and access. During the financial crisis, Greece sharply reduced drug prices and introduced mandatory manufacturer rebates, known as clawbacks, when spending exceeded budget targets. The measures helped contain public spending, but manufacturers delayed launches or withdrew some products. Patients faced restricted or delayed access to innovative oncology drugs, biologics and orphan medicines. Greece is now under EU requirements to reduce clawbacks while maintaining fiscal discipline.

An aging society

Demographic change will add to these pressures. Almost a quarter of Greece’s population is 65 or older, up from about 15% in 2000. Low birth rates and rising chronic disease are increasing demand for healthcare, long-term care and social support. These pressures fall on a workforce already thinned by emigration.

Greece is not a model for the United States to adopt. Its financing and delivery structures are different. But the challenges are familiar: uneven access, workforce shortages, pressure on public budgets, payment incentives and the cost of bringing innovation to patients. Universal coverage is a starting point, not a measure of system performance by itself. The real test is whether a system has the capacity, financing and organization to deliver care when and where patients need it.

Perry Cohen, Pharm.D., is CEO of The Pharmacy Group and the TPG family of companies, including TPG International Health Academy, and a longtime member of the Managed Healthcare Executive editorial advisory board.


Related to this article